E Ntikoudi1, M Kiagia, P Boura, K N Syrigos. 1. Oncology Unit, Third Department of Medicine, Athens University School of Medicine, Sotiria General Hospital, Building Z, 152 Mesogion Avenue, 115 27 Athens, Greece. Electronic address: dikoudi@yahoo.com.
Abstract
INTRODUCTION: Adipose tissue secretes numerous bioactive peptides, collectively termed "adipocytokines" or "adipokines". Adipokines act in a paracrine, autocrine, or endocrine manner and regulate several physiological and pathological processes. Increasing evidence indicates that adipokines are implicated also in several malignancies, including lung cancer as well. AIM: The aim of this study is to summarize data concerning adipokines in lung cancer pathogenesis, prognosis and survival; the role of adipokines in lung cancer cachexia is also examined. MATERIALS AND METHODS: A systematic literature search was performed in the electronic database of Medline. Several studies and review articles met the inclusion criteria. RESULTS: Leptin and adiponectin are the best studied adipokines. The majority of the relevant studies has investigated the potential correlations mainly between leptin, adiponectin, and sometimes also resistin, and nutritional status, systemic inflammation of lung cancer or lung cancer cachexia and have also assessed their prognostic significance. Few other studies have studied genetic variations in leptin, leptin receptor and adiponectin genes and their association with lung cancer susceptibility and prognosis. The ongoing list of adipokines associated with lung cancer also includes resistin, chemerin, and visfatin. CONCLUSIONS: Increasing evidence points to the involvement of certain adipocytokines in lung cancer development, progression and prognosis. No conclusive evidence exists so far with regards to the role of adipocytokines in lung cancer cachexia. Future, longitudinal studies are warranted in order to clarify the role of adipocytokines in lung cancer and also uncover adipocytokines as novel therapeutic targets.
INTRODUCTION: Adipose tissue secretes numerous bioactive peptides, collectively termed "adipocytokines" or "adipokines". Adipokines act in a paracrine, autocrine, or endocrine manner and regulate several physiological and pathological processes. Increasing evidence indicates that adipokines are implicated also in several malignancies, including lung cancer as well. AIM: The aim of this study is to summarize data concerning adipokines in lung cancer pathogenesis, prognosis and survival; the role of adipokines in lung cancer cachexia is also examined. MATERIALS AND METHODS: A systematic literature search was performed in the electronic database of Medline. Several studies and review articles met the inclusion criteria. RESULTS: Leptin and adiponectin are the best studied adipokines. The majority of the relevant studies has investigated the potential correlations mainly between leptin, adiponectin, and sometimes also resistin, and nutritional status, systemic inflammation of lung cancer or lung cancer cachexia and have also assessed their prognostic significance. Few other studies have studied genetic variations in leptin, leptin receptor and adiponectin genes and their association with lung cancer susceptibility and prognosis. The ongoing list of adipokines associated with lung cancer also includes resistin, chemerin, and visfatin. CONCLUSIONS: Increasing evidence points to the involvement of certain adipocytokines in lung cancer development, progression and prognosis. No conclusive evidence exists so far with regards to the role of adipocytokines in lung cancer cachexia. Future, longitudinal studies are warranted in order to clarify the role of adipocytokines in lung cancer and also uncover adipocytokines as novel therapeutic targets.
Authors: Anthony Nardone; Catterina Ferreccio; Johanna Acevedo; Wayne Enanoria; Alden Blair; Allan H Smith; John Balmes; Craig Steinmaus Journal: Environ Res Date: 2017-07-21 Impact factor: 6.498
Authors: Danxia Yu; Wei Zheng; Mattias Johansson; Qing Lan; Yikyung Park; Emily White; Charles E Matthews; Norie Sawada; Yu-Tang Gao; Kim Robien; Rashmi Sinha; Arnulf Langhammer; Rudolf Kaaks; Edward L Giovannucci; Linda M Liao; Yong-Bing Xiang; DeAnn Lazovich; Ulrike Peters; Xuehong Zhang; Bas Bueno-de-Mesquita; Walter C Willett; Shoichiro Tsugane; Yumie Takata; Stephanie A Smith-Warner; William Blot; Xiao-Ou Shu Journal: J Natl Cancer Inst Date: 2018-08-01 Impact factor: 13.506
Authors: Wen Zhou; Geoffrey Liu; Rayjean J Hung; Philip C Haycock; Melinda C Aldrich; Angeline S Andrew; Susanne M Arnold; Heike Bickeböller; Stig E Bojesen; Paul Brennan; Hans Brunnström; Olle Melander; Neil E Caporaso; Maria Teresa Landi; Chu Chen; Gary E Goodman; David C Christiani; Angela Cox; John K Field; Mikael Johansson; Lambertus A Kiemeney; Stephen Lam; Philip Lazarus; Loïc Le Marchand; Gad Rennert; Angela Risch; Matthew B Schabath; Sanjay S Shete; Adonina Tardón; Shanbeh Zienolddiny; Hongbing Shen; Christopher I Amos Journal: Int J Cancer Date: 2020-09-23 Impact factor: 7.396